Aarron Willingham | Senior Principal Scientist And Group Leader
Merck And Co Inc

Aarron Willingham, Senior Principal Scientist And Group Leader, Merck And Co Inc

Aarron Willingham is the Executive Director of Early Biologics and Technologies and a member of the leadership team for Discovery Biologics at Merck and Co. His team operates at the intersection of technology platforms, protein engineering, antibody discovery, cellular assays, and bioconjugates to build next generation biotherapeutics with ground-breaking properties. Aarron’s passion for platform technologies started with Affymetrix in 2005 and then brought him to Merck in 2008 to work on RNA therapeutics before pivoting to Biologics in 2011. He completed postdoctoral training at the Scripps Research Institute and holds a PhD from UC San Diego.

Appearances:



Festival of Biologics Day 2 @ 16:40

Modulating Fc effector function to improve therapeutic modalities

     
  • Evaluation of Fc effector mutations on ADCC and CDC
  • Hexameric IgG formats and complement binding
  • Immune stimulating ADCs that leverage ADCP
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers